INSM vs LQDA
INSM: A biopharmaceutical company with approved rare respiratory therapies (ARIKAYCE for MAC lung disease, BRINSUPRI for bronchiectasis) and a pipeline in respiratory, immunology, and neurological rare diseases. LQDA: Liquidia is a rare-disease biopharmaceutical company commercializing YUTREPIA, a next-generation inhaled treprostinil with proprietary particle engineering, for pulmonary hypertension.
Side-by-side fundamentals
| Metric | INSM | LQDA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $106.64 | $87.04 | |
| Market cap as of 2026-07-23 | $23.4B | $7.7B | |
| P/E as of 2026-07-23 | n/a | 347.02 | |
| Net margin as of 2026-07-23 | -144.4% | +7.7% | LQDA higher |
| Gross margin as of 2026-07-23 | +81.8% | +91.8% | LQDA higher |
| Operating margin as of 2026-07-23 | -140.6% | +15.8% | LQDA higher |
| ROE as of 2026-07-23 | -130.1% | +46.8% | LQDA higher |
| ROA as of 2026-07-23 | -51.6% | +7.1% | LQDA higher |
| Debt / equity as of 2026-07-23 | 1.03 | 1.64 | INSM lower |
| Revenue growth (YoY) as of 2026-07-23 | +115.1% | +1936.7% | LQDA higher |
| Revenue CAGR (3y) SEC XBRL | +35.2% | +115.0% | LQDA higher |
| Beta as of 2026-07-23 | 0.80 | 0.58 | |
| 1-year return as of 2026-07-22 close | +5.7% | +424.3% | LQDA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.